Treatment of infections caused by organisms sensitive to levofloxacin, such as:
– Nosocomial pneumonia.
– Community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae or Chlamydophila pneumoniae.
– Complicated skin and skin structure infections.
– Uncomplicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus ho?c Acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia .
– Acute bacterial sinusitis: Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions], and for some patients with acute bacterial sinusitis is self-limiting, reserve levofloxacin for treatment of acute bacterial sinusitis in patients who have no alternative treatment options.

This is only the preview. Please check here for the full indication.

Anatomical Therapeutic Chemical: J
Dosage form: Film coated tablet
Packaging: 10's x 3
Therapeutic area: Active pharmaceutical ingredient: